AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

AbCellera Biologics Inc. (ABCL) reported $9.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -$0.17 for the same period compares to -$0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.While investors scrutinize revenue and earnings changes year-over-year and how they com ...